Shares of Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) have received an average rating of “Buy” from the six research firms that are presently covering the firm, Marketbeat.com reports. Two investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. The average 12-month price objective among brokers that have updated their coverage on the stock in the last year is $11.50.
Several research firms recently weighed in on SPPI. HC Wainwright reissued a “buy” rating and issued a $14.00 target price on shares of Spectrum Pharmaceuticals in a research note on Thursday. Jefferies Group LLC set a $9.00 target price on shares of Spectrum Pharmaceuticals and gave the company a “buy” rating in a research note on Friday, August 25th. Zacks Investment Research cut shares of Spectrum Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Friday, August 18th. ValuEngine raised shares of Spectrum Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Thursday, August 17th. Finally, BidaskClub cut shares of Spectrum Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Monday, July 31st.
Spectrum Pharmaceuticals (NASDAQ SPPI) traded up 0.99% during mid-day trading on Wednesday, reaching $10.17. 2,632,187 shares of the company’s stock traded hands. The stock’s market cap is $799.12 million. Spectrum Pharmaceuticals has a 1-year low of $3.21 and a 1-year high of $10.77. The firm has a 50-day moving average price of $9.28 and a 200-day moving average price of $7.35.
Spectrum Pharmaceuticals (NASDAQ:SPPI) last issued its quarterly earnings results on Thursday, August 3rd. The biotechnology company reported ($0.26) earnings per share for the quarter, topping the consensus estimate of ($0.27) by $0.01. Spectrum Pharmaceuticals had a negative net margin of 59.33% and a negative return on equity of 30.95%. The company had revenue of $34.30 million during the quarter, compared to analysts’ expectations of $30.50 million. During the same period last year, the business earned ($0.35) EPS. The business’s quarterly revenue was up 1.0% on a year-over-year basis. Equities research analysts anticipate that Spectrum Pharmaceuticals will post ($1.03) EPS for the current fiscal year.
Institutional investors have recently made changes to their positions in the business. Principal Financial Group Inc. lifted its holdings in Spectrum Pharmaceuticals by 4.6% during the 1st quarter. Principal Financial Group Inc. now owns 553,451 shares of the biotechnology company’s stock valued at $3,598,000 after purchasing an additional 24,245 shares during the last quarter. Alambic Investment Management L.P. lifted its holdings in Spectrum Pharmaceuticals by 0.9% during the 1st quarter. Alambic Investment Management L.P. now owns 287,601 shares of the biotechnology company’s stock valued at $1,869,000 after purchasing an additional 2,500 shares during the last quarter. Louisiana State Employees Retirement System lifted its holdings in Spectrum Pharmaceuticals by 2.8% during the 1st quarter. Louisiana State Employees Retirement System now owns 28,900 shares of the biotechnology company’s stock valued at $188,000 after purchasing an additional 800 shares during the last quarter. Denver Investment Advisors LLC acquired a new stake in Spectrum Pharmaceuticals during the 1st quarter valued at $106,000. Finally, State of Tennessee Treasury Department lifted its holdings in shares of Spectrum Pharmaceuticals by 17.8% during the first quarter. State of Tennessee Treasury Department now owns 66,461 shares of the biotechnology company’s stock worth $432,000 after buying an additional 10,030 shares in the last quarter. 66.09% of the stock is owned by institutional investors and hedge funds.
TRADEMARK VIOLATION WARNING: “Brokerages Set Spectrum Pharmaceuticals, Inc. (SPPI) Target Price at $11.00” was originally posted by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are accessing this piece on another publication, it was illegally copied and republished in violation of U.S. and international trademark & copyright law. The legal version of this piece can be viewed at https://ledgergazette.com/2017/09/16/brokerages-set-spectrum-pharmaceuticals-inc-sppi-target-price-at-11-00.html.
About Spectrum Pharmaceuticals
Spectrum Pharmaceuticals, Inc is a biotechnology company. The Company operates through developing and commercializing oncology and hematology drug products segment. It has a product portfolio consisting of both commercial stage and development stage products that address various cancer types. The Company has six approved oncology/hematology products that target different types of cancer, including non-Hodgkin’s lymphoma (NHL), advanced metastatic colorectal cancer (mCRC), acute lymphoblastic leukemia (ALL) and multiple myeloma (MM).
Receive News & Ratings for Spectrum Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spectrum Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.